Disclosures: Chinmay Bera: Nothing to Disclose, Nashla Hamdan: Nothing to Disclose, Heather Kosick: Nothing to Disclose, Nader Allam: Nothing to Disclose, Mina Fakhriyehasl: Nothing to Disclose, Kartik Jhaveri: Nothing to Disclose, Keyur Patel: Novo-Nordisk: Consultant, Gilead Sciences: Consultant, Merck: Consultant, Resalis: Advisor 615 DIABETES IS A RISK FACTOR FOR SARCOPENIA OF PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS-DRIVEN CIRRHOSIS Shinya Sato 1 Hiroaki Takaya 1 NORIHISA NISHIMURA 1 KOSUKE KAJI 1 Tadashi Namisaki 1 Takemi Akahane 1 Hitoshi Yoshiji 1 , 1 Nara Medical University Background: The relevance of metabolic disorders in causing liver diseases led the recent proposal by the international expert panel to rename the fatty liver as Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
Stay tuned to Brandsynario for latest news and updates
8.1 Skin samples Skin -Syn is not able to distinguish between PD patients and healthy controls, which, however, may be highly efficient in identifying -Syn seed activity in skin samples
doi: 10.1167/iovs.61.10.49 363 WangCWangKLiP
Bacterial ghosts for targeting delivery and subsequent responsive release of ciprofloxacin to destruct intracellular bacteria
The mist brightens, soothes and balances the skin while promoting a more even and radiant complexion